Loading…
China Resources-affiliated maker of hospital generic and injectable drugs across a broad range of therapeutic areas.
China Resources-affiliated maker of hospital generic and injectable drugs across a broad range of therapeutic areas.
Sells drugs through distributors to public hospitals, where prices for many generics are set by national volume-based procurement auctions, so winning a contract trades lower prices for guaranteed volume. China Resources, the state-owned conglomerate, controls it and helps with distribution.
In one line: A Chinese hospital-generics Hospira.
Moat: none (scale, distribution). Broad generic portfolio and China Resources group distribution support, but limited pricing power.
Headquarters: Beijing, China · Employees: 13,184
Size China Resources Double-Crane Pharmaceutical (600062.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $2.50B, the 1031st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥16.07 on 6 Nov 2026.
Performance Over six months the shares fell 10.0%, against -1.5% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue fell 1.5% over the last twelve months (peer median +9.1%); the operating margin is 12.6% (peer median 16.4%).
Valuation It trades at 9.8× forward earnings against a peer median of 18.3× (2nd cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.4 points above its cost of capital (5.0% WACC).
Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥10.8B | CN¥10.9B | CN¥11.1B | CN¥11.2B | CN¥9.57B |
| Revenue growth | — | -2% | -1% | +17% | — |
| Gross profit | CN¥6.46B | CN¥5.97B | CN¥6.08B | CN¥6.11B | CN¥4.97B |
| EBITDA | n/a | CN¥2.47B | CN¥2.37B | CN¥2.39B | CN¥1.80B |
| Net income | CN¥1.57B | CN¥1.65B | CN¥1.63B | CN¥1.67B | CN¥1.18B |
| Free cash flow | CN¥985M | CN¥1.00B | CN¥1.21B | CN¥1.33B | CN¥984M |
| Capital expenditure | CN¥557M | CN¥620M | CN¥637M | CN¥614M | CN¥527M |
| Total debt | CN¥2.14B | CN¥1.27B | CN¥1.32B | CN¥467M | CN¥440M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Resources Double-Crane Pharmaceutical 600062.SS | $2.50B | -10% | -1% | 13% | 9.8× | -8.3% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | $1.76B | -25% | -13% | 12% | 63.3× | 14.7% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
| Sichuan Kelun Pharmaceutical 002422.SZ | $10.8B | +30% | 0% | 9% | 37.3× | 7.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600062.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.6% | +2.9% | 6th lowest of 21 |
| 6-month return | -10.0% | -1.5% | 5th lowest of 21 |
| Distance from 52-week high | -18.7% | -18.5% | 11th highest of 21 |
| Revenue growth (TTM) | -1.5% | +9.1% | 8th lowest of 21 |
| Operating margin | 12.6% | 16.4% | 8th lowest of 21 |
| Forward P/E | 9.8× | 18.3× | 2nd cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -8.3% | 0.9% | 2nd least demanding of 20 |
| Growth delivered (Del g) | +5.3% | +5.9% | 8th lowest of 20 |
| Hurdle (Req g minus delivered) | -13.6 pp | -7.3 pp | 7th least demanding of 20 |
| ROIC minus cost of capital | +5.4 pp | +2.7 pp | 10th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 9.8× | -8.3% | +5.3% |
| By-health 300146.SZ | China | $2.61B | -1% | +10% | 11% | 25.0× | 5.1% | +0.6% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% | +11.6% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 24.9× | 23.5% | +10.6% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $3.02B | -9% | -4% | -13% | n/a | 5.2% | +1.0% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 12.6× | -3.0% | +4.4% |
| Bausch Health Companies BHC.TO | Canada | $3.09B | +48% | +10% | 27% | 1.9× | -14.5% | +5.9% |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | n/a | -0.8% | -2.1% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.13B | +35% | -14% | 9% | 80.3× | 34.7% | +5.9% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | n/a | 5.3% | +10.4% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | n/a | -1.1% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $4.02B | -6% | +32% | 21% | 18.1× | -3.2% | -2.2% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Dong-E-E-Jiao 000423.SZ | China | $4.80B | -8% | +8% | 29% | 17.1× | -4.6% | +14.5% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |